Targeting Soluble Adenylyl Cyclase for On-Demand Contraception
Physiology · 01.09.2026 · 41 (5) · 534-544
DOI: 10.1152/physiol.00009.2026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Physiology, erschienen am 01.09.2026. Verfasst von Erin R Gardner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gardner Pharmacology, LLC, Vienna, Virginia, United States. Hauptthemen laut MEDLINE: Adenylyl Cyclases, Contraception, Contraceptive Agents, Male, Spermatozoa. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Male Contraceptive Initiative (MCI), HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Soluble adenylyl cyclase (sAC; ADCY10) is an evolutionarily ancient, intracellular source of cAMP that is molecularly and mechanistically distinct from the more widely studied, hormone-responsive, G protein-regulated transmembrane adenylyl cyclases. Unlike other mammalian cyclases, sAC is most abundantly expressed in male germ cells and is directly regulated by bicarbonate and calcium. Genetic and pharmacological evidence in rodents and humans establishes sAC as essential for male fertility: loss of sAC activity yields immotile sperm incapable of fertilizing the egg, resulting in male-specific infertility. These features position sAC as a promising target for developing nonhormonal, on-demand contraceptives suitable for men and women. A proof-of-concept inhibitor has demonstrated a rapid, reversible contraceptive effect in vivo in mice, but translation to a clinical product must address challenges inherent to on-demand sperm-targeted pharmacology. In addition to ensuring a high safety margin and navigating an emerging regulatory and commercial landscape, common to any male contraceptive, on-demand male contraception must define the onset/duration of efficacy while ensuring persistent inactivation of sperm function after ejaculation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gardner Pharmacology, LLC, Vienna, Virginia, United States.
- Sacyl Pharmaceuticals, Inc., Delaware, United States.
- Department of Pharmacology, Weill Cornell Medicine, New York, New York, United States.
ORCID-Profile: Jochen Buck, Lonny R Levin
Förderung
- NICHD NIH HHS
- Male Contraceptive Initiative (MCI)
- HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Gardner, E. R., Kopf, G. S., Buck, J., & Levin, L. R. (2026). Targeting Soluble Adenylyl Cyclase for On-Demand Contraception. Physiology, 41(5), 534-544. https://doi.org/10.1152/physiol.00009.2026
Vancouver
Gardner ER, Kopf GS, Buck J, Levin LR. Targeting Soluble Adenylyl Cyclase for On-Demand Contraception. Physiology. 2026;41(5):534-544. doi:10.1152/physiol.00009.2026
BibTeX
@article{Gardner2026,
author = {Gardner, Erin R and Kopf, Gregory S and Buck, Jochen and Levin, Lonny R},
title = {Targeting Soluble Adenylyl Cyclase for On-Demand Contraception},
journal = {Physiology},
year = {2026},
volume = {41},
number = {5},
pages = {534--544},
doi = {10.1152/physiol.00009.2026}
}
EUVIMED